CorMedix (CRMD) Reiterated at Market Outperform by Citizens on Positive REZZAYO Results

April 28, 2026 4:18 AM

Citizens analyst Jason N. Butler reiterated a Market Outperform rating and $19.00 price target on CorMedix (NASDAQ: CRMD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found